Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02912195 · ClinicalTrials.gov registry record · Phase 4

Intravenous Lidocaine Versus Morphine for Severe Pain in the ED

A Phase 4 study of Pain, sponsored by Alameda Health System.

Completed
Registry status
Phase 4
Development phase
32
Enrollment target
1
Study location

NCT02912195: Completed Phase 4 study of Pain, sponsored by Alameda Health System.

NCT02912195 is a Phase 4 study of Pain that has completed, run by Alameda Health System. The registered enrollment target is 32 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02912195, a Phase 4 study of Pain, has completed, sponsored by Alameda Health System.

COMPLETED
Registry status
Phase 4
Development phase
32 participants
Enrollment target
1
Study location

Study Summary

Objective: Evaluate the analgesic efficacy of intravenous (IV) lidocaine versus provider chosen dose of IV morphine for the treatment of severe pain in the emergency department. Study design: Open-label, randomized controlled pilot study.

Primary Outcome

Pain score is rated on the Numeric Rating Scale from 0-10. 0 represents no pain and 10 represents the worst possible pain.

Conditions Studied

Interventions

  • DRUG Intravenous lidocaine
  • DRUG Intravenous morphine

Study Locations (1)

California

  • Alameda Health System, Highland Hospital - Oakland

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2016-03
Est. Completion 2016-09
Phase Phase 4
Alameda Health System

3 total trials

What the finished NCT02912195 record still lists

NCT02912195 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 304-participant average among 374 other Pain trials with a reported enrollment target (89% lower).

The record links to 1 condition, with Pain appearing as the primary indexed condition, and to 2 interventions - of which Intravenous lidocaine is the first listed.

NCT02912195 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT02912195 about?

NCT02912195 is a clinical study titled "Intravenous Lidocaine Versus Morphine for Severe Pain in the ED". Objective: Evaluate the analgesic efficacy of intravenous (IV) lidocaine versus provider chosen dose of IV morphine for the treatment of severe pain in the emergency department. Study design: Open-label, randomized controlled pilot study.

What is the current status of trial NCT02912195?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2016-03. Estimated completion is 2016-09.

What conditions does trial NCT02912195 study?

This clinical trial studies the following conditions: Pain.

What interventions are being tested in trial NCT02912195?

The interventions under investigation include: Intravenous lidocaine (DRUG), Intravenous morphine (DRUG).

Who is sponsoring clinical trial NCT02912195?

This trial is sponsored by Alameda Health System, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02912195 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02912195's enrollment target sits among peer trials

32 307th of 374 higher than 66 of 374 other Pain trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02445781 · 32 participants · Early Phase 1

    Differing Levels of Hypoglycemia

  • NCT02792270 · 32 participants · NA

    Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT

  • NCT03068910 · 32 participants · Early Phase 1

    Hyperandrogenemia and Altered Day-night LH Pulse Patterns

  • NCT03208868 · 32 participants · NA

    Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02912195, the US trial registry maintained by the National Library of Medicine. NCT02912195 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.